Bioinformatic Analysis of Potential Biomarker for hsa-miR-196b-5p in Mesothelioma

Sohn, Eun Jung

doi:10.1089/gtmb.2021.0147

Cited by 2 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This analysis identified geldanamycin as the only drug to be significantly associated with the invasive signature in both databases (LINCS L1000; p value < 0.0001, CMAP; p. value = 0.012, S1 File). Geldanamycin and its derivatives are inhibitors of heat-shock protein 90 [27,28], and previous studies demonstrated significant inhibitory effects on myogenic differentiation and muscle regeneration [29,30], as well as direct anti-cancer effects, including in mesothelioma in vitro [31,32]. Together, these results suggested that geldanamycin might have anti-cancer activity in pleural mesothelioma.…”

Section: Lincs and Cmap Analyses Identify Geldanamycin As A Potential...mentioning

confidence: 71%

Geldanamycin treatment does not result in anti-cancer activity in a preclinical model of orthotopic mesothelioma

et al. 2023

View full text Add to dashboard Cite

Mesothelioma is characterised by its aggressive invasive behaviour, affecting the surrounding tissues of the pleura or peritoneum. We compared an invasive pleural model with a non-invasive subcutaneous model of mesothelioma and performed transcriptomic analyses on the tumour samples. Invasive pleural tumours were characterised by a transcriptomic signature enriched for genes associated with MEF2C and MYOCD signaling, muscle differentiation and myogenesis. Further analysis using the CMap and LINCS databases identified geldanamycin as a potential antagonist of this signature, so we evaluated its potential in vitro and in vivo. Nanomolar concentrations of geldanamycin significantly reduced cell growth, invasion, and migration in vitro. However, administration of geldanamycin in vivo did not result in significant anti-cancer activity. Our findings show that myogenesis and muscle differentiation pathways are upregulated in pleural mesothelioma which may be related to the invasive behaviour. However, geldanamycin as a single agent does not appear to be a viable treatment for mesothelioma.

show abstract

Section: Lincs and Cmap Analyses Identify Geldanamycin As A Potential...mentioning

confidence: 71%

Geldanamycin treatment does not result in anti-cancer activity in a preclinical model of orthotopic mesothelioma

et al. 2023

View full text Add to dashboard Cite

show abstract

“…This analysis identified geldanamycin as the only drug to be significantly associated with the invasive signature in both databases (LINCS L1000; p value < 0.0001, CMAP; p. value = 0.012, Supplementary Data S1). Geldanamycin and its derivatives are inhibitors of heat-shock protein 90 (27) (28), and previous studies demonstrated significant inhibitory effects on myogenic differentiation and muscle regeneration (29) (30), as well as direct anti-cancer effects, including in mesothelioma in vitro (31) (32). Together, these results suggested that geldanamycin might have anti-cancer activity in pleural mesothelioma.…”

Section: Resultsmentioning

confidence: 99%

Geldanamycin treatment does not result in anti-cancer activity in a preclinical model of orthotopic mesothelioma

Morales

Rinaldi

Jong

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

Bioinformatic Analysis of Potential Biomarker for hsa-miR-196b-5p in Mesothelioma

Cited by 2 publications

References 19 publications

Geldanamycin treatment does not result in anti-cancer activity in a preclinical model of orthotopic mesothelioma

Geldanamycin treatment does not result in anti-cancer activity in a preclinical model of orthotopic mesothelioma

Geldanamycin treatment does not result in anti-cancer activity in a preclinical model of orthotopic mesothelioma

Contact Info

Product

Resources

About